Intersecção discusses how drug prohibition fuels deforestation, violence, and inequality across the region, linking the 'war on drugs' to the global climate crisis and calling for ecological harm reduction and rights-based regulation.
This collection examines Europe’s harm reduction journey, including early successes, uneven implementation, securitisation, stigma and medicalisation; and proposes a reframed, people-led approach centring wellbeing, acknowledging drug-use benefits, and advancing rights-based reforms.
The New Zealand Drug Foundation urges reform of outdated drug laws, calling for decriminalisation, Māori-led health approaches and investment in harm reduction to build safer, fairer, evidence-based policies for Aotearoa New Zealand.
The HIV Legal Network argues that laws criminalising simple possession and drug trafficking entrench racism and stigma, deepen inequality, and endanger health and safety by pushing drug use into isolation and heightening the risk of overdose.
EHRA, alongside C-EHRN, EuroNPUD and DPNSEE, state that the exclusion, fragmentation, and underfunding of harm reduction and essential health services within Universal Health Coverage systems cause people who use drugs to experience disproportionately poor health outcomes across Europe.
WHRIN's global campaign around the International Day for the Elimination of Violence against Women calls groups worldwide to join the 16 Days of Action with activities highlighting violence against women and gender diverse people who use drugs.
EHRA, Union for Equity and Health, and PULS urge the Committee to interrogate Moldova’s punitive drug policies, which criminalise people who use drugs, restrict health and employment outcomes, and deepen stigma.
Civil society exposes punitive harms and rights violations, while urging a shift towards health, harm reduction, decriminalisation, justice reform, and sustainable livelihoods.
Youth RISE explains that current drug education, often focused on fear-mongering and punitive approaches, fails to equip young people with the knowledge and tools they need to stay safe.
Bewley-Taylor et al. find the GDPI useful for comparing international drug policy, and suggest improvements to better handle uncertainty and diverse data.
